Diabetic Nephropathy Type 2 clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Atrasentan in Patients With Proteinuric Glomerular Diseases
open to eligible people ages 18 years and up
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
at UCLA
Last updated: